Incyte Corp. has patented heteroaryl fluoroalkenes acting as diacylglycerol kinase α (DGK-α) and/or diacylglycerol kinase ζ (DGK-ζ) inhibitors and thus reported to be useful for the treatment of cancer.

Rome Therapeutics Inc. has synthesized cyclopentene-oxymethylene phosphonamidate compounds acting as LINE-1 retrotransposable element ORF1 protein (L1RE1) and/or HERV-K reverse transcriptase inhibitors.

Insilico Medicine Inc. has identified new salt-inducible kinase inhibitors potentially useful for the treatment of cancer.

An Eli Lilly & Co. patent describes new glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes type 2, hyperglycemia and obesity.

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has described cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors reported to be useful for the treatment of psoriatic arthritis, diabetes, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, sepsis, systemic lupus erythematosus and transplant rejection, among others.

Shijiazhuang Discovery Medicine Technology Co. Ltd. has divulged compounds reported to be useful for the treatment of influenza.

Emory University has identified 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Humanwell Healthcare (Group) Co. Ltd. has synthesized transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.

Nanjing China-Australia Institute of Translational Medicine Co. Ltd. has disclosed baculoviral IAP repeat-containing protein 3 (BIRC3; IAP1; cIAP2), baculoviral IAP repeat-containing protein 2 (BIRC2; IAP2; cIAP1) and E3 ubiquitin-protein ligase XIAP (XIAP; BIRC4; IAP3) inhibitors reported to be useful for the treatment of cancer.

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has described serine/threonine-protein kinase ULK1 inhibitors reported to be useful for the treatment of cancer.